| Jonathan Eric Wickiser, MD | |
|
5323 Harry Hines Blvd, Dallas, TX 75390-7201 | |
| (214) 730-5437 | |
| Not Available |
| Full Name | Jonathan Eric Wickiser |
|---|---|
| Gender | Male |
| Speciality | Pediatrics - Pediatric Hematology-oncology |
| Location | 5323 Harry Hines Blvd, Dallas, Texas |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1194740688 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2080P0207X | Pediatrics - Pediatric Hematology-oncology | M4653 (Texas) | Primary |
| 208000000X | Pediatrics | M4653 (Texas) | Secondary |
| Entity Name | University Of Texas Southwestern Medical Center At Dallas |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1972579365 PECOS PAC ID: 0648188250 Enrollment ID: O20031106000792 |
News Archive
Ranbaxy Laboratories Limited, along with its wholly owned subsidiary Ranbaxy Pharmaceuticals Inc. (collectively, "Ranbaxy"), announced today that they have reached an agreement with Takeda Pharmaceutical Company Limited and Takeda Pharmaceuticals North America resolving outstanding patent litigation related to Ranbaxy's generic equivalent version of Actos® (Pioglitazone Hydrochloride) 15 mg, 30 mg and 45 mg tablets.
In the first study using magnetic resonance imaging (MRI) to evaluate cardiovascular risk in World Trade Center (WTC) first responders, researchers from Mount Sinai School of Medicine have found that the responders who experienced high levels of exposure to the initial dust cloud on September 11, 2001, demonstrate high-risk features of atherosclerosis.
MAP Pharmaceuticals, Inc. today reported successful results from a thorough QT trial of its investigational LEVADEX™ orally inhaled migraine therapy. The trial evaluated the potential of a supra-therapeutic dose to cause an increase in the QT interval. Results of the trial showed that a supra-therapeutic dose of LEVADEX does not increase QTc intervals. LEVADEX is a novel orally inhaled migraine therapy that has completed Phase 3 efficacy development for the acute treatment of migraine.
InstaCare Corp. a leading provider of prescription diagnostics, home testing products for the chronically ill, a leading fulfillment provider of direct to patient diabetes programs, and a leading developer of revolutionary cell phone centric e-health products and technologies, today announced that its operating subsidiary, Pharma Tech Solutions, Inc., has significantly expanded its agreement to control, manage and distribute the novel at-home diagnostic product, the Shasta Genstrip.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jonathan Eric Wickiser, MD Po Box 845347, Dallas, TX 75284-5347 Ph: (214) 730-5437 | Jonathan Eric Wickiser, MD 5323 Harry Hines Blvd, Dallas, TX 75390-7201 Ph: (214) 730-5437 |
News Archive
Ranbaxy Laboratories Limited, along with its wholly owned subsidiary Ranbaxy Pharmaceuticals Inc. (collectively, "Ranbaxy"), announced today that they have reached an agreement with Takeda Pharmaceutical Company Limited and Takeda Pharmaceuticals North America resolving outstanding patent litigation related to Ranbaxy's generic equivalent version of Actos® (Pioglitazone Hydrochloride) 15 mg, 30 mg and 45 mg tablets.
In the first study using magnetic resonance imaging (MRI) to evaluate cardiovascular risk in World Trade Center (WTC) first responders, researchers from Mount Sinai School of Medicine have found that the responders who experienced high levels of exposure to the initial dust cloud on September 11, 2001, demonstrate high-risk features of atherosclerosis.
MAP Pharmaceuticals, Inc. today reported successful results from a thorough QT trial of its investigational LEVADEX™ orally inhaled migraine therapy. The trial evaluated the potential of a supra-therapeutic dose to cause an increase in the QT interval. Results of the trial showed that a supra-therapeutic dose of LEVADEX does not increase QTc intervals. LEVADEX is a novel orally inhaled migraine therapy that has completed Phase 3 efficacy development for the acute treatment of migraine.
InstaCare Corp. a leading provider of prescription diagnostics, home testing products for the chronically ill, a leading fulfillment provider of direct to patient diabetes programs, and a leading developer of revolutionary cell phone centric e-health products and technologies, today announced that its operating subsidiary, Pharma Tech Solutions, Inc., has significantly expanded its agreement to control, manage and distribute the novel at-home diagnostic product, the Shasta Genstrip.
› Verified 6 days ago
Dr. Jyothsna Gattineni, M.D. Pediatrics Medicare: Accepting Medicare Assignments Practice Location: 5323 Harry Hines Blvd, Dallas, TX 75390 Phone: 214-648-3438 | |
Ruth Osei Fordjour, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 12221 Merit Dr, Suite 1500, Dallas, TX 75251 Phone: 214-957-4754 | |
Dr. Alecia Curlene Nero, M.D. Pediatrics Medicare: Accepting Medicare Assignments Practice Location: 5323 Harry Hines Blvd, Dallas, TX 75390 Phone: 214-648-4180 | |
Dr. Sravani Avula, M.D. Pediatrics Medicare: Accepting Medicare Assignments Practice Location: 5323 Harry Hines Blvd, Dallas, TX 75390 Phone: 214-730-5437 | |
Asif Zia Khattak, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 3500 Gaston Ave, Dallas, TX 75246 Phone: 214-820-7604 | |
Sadia Malik, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 5323 Harry Hines Boulevard, Dallas, TX 75390 Phone: 214-456-2533 Fax: 214-456-8130 | |
Sana Jamil Siddiqui, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 5323 Harry Hines Boulevard, Dallas, TX 75390 Phone: 214-456-0488 Fax: 214-456-4486 |